Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions

被引:160
作者
Broisat, Alexis [1 ,2 ]
Hernot, Sophie [3 ]
Toczek, Jakub [1 ,2 ]
De Vos, Jens [3 ,4 ,5 ]
Riou, Laurent M. [1 ,2 ]
Martin, Sandrine [1 ,2 ,4 ,5 ]
Ahmadi, Mitra [1 ,2 ]
Thielens, Nicole [6 ]
Wernery, Ulrich [7 ]
Caveliers, Vicky [3 ,8 ]
Muyldermans, Serge
Lahoutte, Tony [3 ,8 ]
Fagret, Daniel [1 ,2 ]
Ghezzi, Catherine [1 ,2 ]
Devoogdt, Nick [3 ]
机构
[1] INSERM, U1039, F-38000 Grenoble, France
[2] Univ Grenoble 1, F-38000 Grenoble, France
[3] Vrije Univ Brussel, Vivo Cellular & Mol Imaging Lab, Brussels, Belgium
[4] Vrije Univ Brussel VIB, Dept Biol Struct, B-1050 Brussels, Belgium
[5] Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium
[6] IBS, CNRS, UMR 5075, Lab Enzymol Mol, Grenoble, France
[7] Cent Vet Res Lab, Dubai, U Arab Emirates
[8] UZ Brussel, Dept Nucl Med, Brussels, Belgium
关键词
atherosclerosis; imaging; nanobody; nuclear medicine; CELL-ADHESION MOLECULE-1; E-SELECTIN; EXPRESSION; PLAQUES; BINDING; MICE; IDENTIFICATION; INFLAMMATION;
D O I
10.1161/CIRCRESAHA.112.265140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions. Objective: We aimed to generate, radiolabel, and evaluate anti-VCAM1 nanobodies for noninvasive detection of atherosclerotic lesions. Methods and Results: Ten anti-VCAM1 nanobodies were generated, radiolabeled with technetium-99m, and screened in vitro on mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in apolipoprotein E-deficient (ApoE(-/-)) mice. Anontargeting control nanobody was used in all experiments to demonstrate specificity. All nanobodies displayed nanomolar affinities for murine VCAM1. Flow cytometry analyses using human human umbilical vein endothelial cells indicated murine and human VCAM1 cross-reactivity for 6 of 10 nanobodies. The lead compound cAbVCAM1-5 was cross-reactive for human VCAM1 and exhibited high lesion-to-control (4.95+/-0.85), lesion-to-heart (8.30+/-1.11), and lesion-to-blood ratios (4.32+/-0.48) (P<0.05 versus control C57Bl/6J mice). Aortic arch atherosclerotic lesions of ApoE(-/-) mice were successfully identified by single-photon emission computed tomography imaging. Tc-99m-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in VCAM1-positive lesions. Conclusions: The Tc-99m-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation. (Circ Res. 2012;110:927-937.)
引用
收藏
页码:927 / 937
页数:11
相关论文
共 37 条
  • [1] Differential Thy-1 expression by splenic fibroblasts defines functionally distinct subsets
    Borrello, MA
    Phipps, RP
    [J]. CELLULAR IMMUNOLOGY, 1996, 173 (02) : 198 - 206
  • [2] Comprehensive analysis of lymph node stroma-expressed Ig superfamily members reveals redundant and nonredundant roles for ICAM-1, ICAM-2, and VCAM-1 in lymphocyte homing
    Boscacci, Remy T.
    Pfeiffer, Friederike
    Gollmer, Kathrin
    Checa Sevilla, Ana Isabel
    Maria Martin, Ana
    Soriano, Silvia Fernandez
    Natale, Daniela
    Henrickson, Sarah
    von Andrian, Ulrich H.
    Fukui, Yoshinori
    Mellado, Mario
    Deutsch, Urban
    Engelhardt, Britta
    Stein, Jens V.
    [J]. BLOOD, 2010, 116 (06) : 915 - 925
  • [3] Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p
    Broisat, A.
    Riou, L. M.
    Ardisson, V.
    Boturyn, D.
    Dumy, P.
    Fagret, D.
    Ghezzi, C.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (06) : 830 - 840
  • [4] Antigen targeted to secondary lymphoid organs via vascular cell adhesion molecule (VCAM) enhances an immune response
    Dyer, CM
    Lew, AM
    [J]. VACCINE, 2003, 21 (17-18) : 2115 - 2121
  • [5] Atherothrombosis and high-risk plaque Part I: Evolving concepts
    Fuster, V
    Moreno, PR
    Fayad, ZA
    Corti, R
    Badimon, JJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) : 937 - 954
  • [6] Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT
    Gainkam, Lea Olive Tchouate
    Huang, Lieven
    Caveliers, Vicky
    Keyaerts, Marleen
    Hernot, Sophie
    Vaneycken, Ilse
    Vanhove, Christian
    Revets, Hilde
    De Baetselier, Patrick
    Lahoutte, Tony
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (05) : 788 - 795
  • [7] Selection and identification of single domain antibody fragments from camel heavy-chain antibodies
    Ghahroudi, MA
    Desmyter, A
    Wyns, L
    Hamers, R
    Muyldermans, S
    [J]. FEBS LETTERS, 1997, 414 (03) : 521 - 526
  • [8] Hernot S, 2011, J CONTROL RELEA 1216
  • [9] Adhesion molecules and atherogenesis
    Huo, Y
    Ley, K
    [J]. ACTA PHYSIOLOGICA SCANDINAVICA, 2001, 173 (01): : 35 - 43
  • [10] Iiyama K, 1999, CIRC RES, V9, P215